Retinitis pigmentosa is a genetic disorder characterized by progressive degeneration of the retina, leading to gradual vision loss and potential blindness. The market for retinitis treatments is expanding rapidly due to factors such as changing demographics, more awareness, and a rise in the prevalence of the condition globally. Growing age demographics in the population are driving an increasing need for retinitis treatment options. Increased knowledge of the potential consequences of untreated retinitis, such as blindness, is encouraging more people to seek diagnosis and treatment, which is supporting market growth.
New York, USA, May 07, 2024 (GLOBE NEWSWIRE) — Retinitis Pigmentosa Clinical Trial Pipeline Insights Featuring 40+ Companies | DelveInsight
Retinitis pigmentosa is a genetic disorder characterized by progressive degeneration of the retina, leading to gradual vision loss and potential blindness. The market for retinitis treatments is expanding rapidly due to factors such as changing demographics, more awareness, and a rise in the prevalence of the condition globally. Growing age demographics in the population are driving an increasing need for retinitis treatment options. Increased knowledge of the potential consequences of untreated retinitis, such as blindness, is encouraging more people to seek diagnosis and treatment, which is supporting market growth.
DelveInsight’s ‘Retinitis Pigmentosa Pipeline Insight 2024‘ report provides comprehensive global coverage of pipeline retinitis pigmentosa therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the retinitis pigmentosa pipeline domain.
Key Takeaways from the Retinitis Pigmentosa Pipeline Report
-
DelveInsight’s retinitis pigmentosa pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for retinitis pigmentosa treatment.
-
Key retinitis pigmentosa companies such as MeiraGTx, Aldeyra Therapeutics, Inc., SparingVision, Frontera Therapeutics, ProQR Therapeutics, Bionic Sight, Endogena Therapeutics, Nacuity Pharmaceuticals, Kiora Pharmaceuticals, jCyte, Ocugen, Neurotech USA, Nanoscope Therapeutics, ONL Therapeutics, PulseSight Therapeutics, ViGeneron, Beacon Therapeutics, and others are evaluating new retinitis pigmentosa drugs to improve the treatment landscape.
-
Promising retinitis pigmentosa pipeline therapies such as Botaretigene sparoparvovec, ADX-2191, SPVN-06, FT-002, Ultevursen, BS 01, EA-2353, NPI-001, KIO-301, Retinal stem cell therapy, OCU400, NT-501, MCO-010, ONL 1204, PST 611, VG 901, AGTC-501, and others are under different phases of retinitis pigmentosa clinical trials.
-
In April 2024, Ocugen announced that the US Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) amendment to initiate a Phase III clinical trial of OCU400, a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP).
-
In April 2024, ViGeneron announced that the first patient had been dosed in its Phase Ib clinical trial evaluating intravitreal injection of VG901 to treat retinitis pigmentosa (RP) caused by mutations in the CNGA1 gene.
-
In March 2024, Nanoscope Therapeutics announced positive top-line results after the completion of the 2-year Phase IIb RESTORE randomized, controlled clinical trial of its lead program, MCO-010, mutation-agnostic gene therapy for patients with permanent and severe vision loss from advanced retinitis pigmentosa (RP).
-
In February 2024, jCyte announced the successful outcome of its pre-phase III Type B meeting with the US Food and Drug Administration (FDA) held on January 16, 2024. Additionally, the company is gearing up to commence its pivotal US trial for jCell in the second half of 2024.
-
In December 2023, Ocugen announced that the FDA had granted RMAT designation to Ocugen’s investigational product OCU400 for the treatment of retinitis pigmentosa (RP) associated with RHO mutations.
-
In October 2023, Kiora Pharmaceuticals received Investigational New Drug Application approval in Australia to enroll up to six additional patients in the ABACUS study of KIO-301. ABACUS was initially designed to evaluate patients with Retinitis Pigmentosa (RP).
Request a sample and discover the recent advances in retinitis pigmentosa treatment drugs @ Retinitis Pigmentosa Pipeline Report
The retinitis pigmentosa pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage retinitis pigmentosa drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the…
Read More: Retinitis Pigmentosa Clinical Trial Pipeline Insights Featuring 40+ Companies